State of Wisconsin Investment Board purchased a new stake in shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) in the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor purchased 26,000 shares of the company’s stock, valued at approximately $235,000. State of Wisconsin Investment Board owned about 0.06% of Karyopharm Therapeutics at the end of the most recent quarter.

A number of other institutional investors have also recently made changes to their positions in the stock. Bank of America Corp DE raised its position in Karyopharm Therapeutics by 0.7% during the first quarter. Bank of America Corp DE now owns 46,127 shares of the company’s stock valued at $592,000 after purchasing an additional 308 shares during the period. American International Group Inc. raised its holdings in shares of Karyopharm Therapeutics by 20.9% in the first quarter. American International Group Inc. now owns 16,422 shares of the company’s stock worth $211,000 after buying an additional 2,836 shares during the period. Schwab Charles Investment Management Inc. raised its holdings in shares of Karyopharm Therapeutics by 4.5% in the first quarter. Schwab Charles Investment Management Inc. now owns 86,514 shares of the company’s stock worth $1,111,000 after buying an additional 3,762 shares during the period. Swiss National Bank raised its holdings in shares of Karyopharm Therapeutics by 10.9% in the first quarter. Swiss National Bank now owns 40,850 shares of the company’s stock worth $525,000 after buying an additional 4,000 shares during the period. Finally, Teachers Advisors LLC raised its holdings in shares of Karyopharm Therapeutics by 15.0% in the fourth quarter. Teachers Advisors LLC now owns 41,436 shares of the company’s stock worth $389,000 after buying an additional 5,419 shares during the period. 58.97% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION WARNING: “State of Wisconsin Investment Board Takes $235,000 Position in Karyopharm Therapeutics Inc. (KPTI)” was posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are viewing this piece of content on another publication, it was illegally copied and reposted in violation of United States & international copyright laws. The original version of this piece of content can be read at https://www.thecerbatgem.com/2017/09/16/state-of-wisconsin-investment-board-takes-235000-position-in-karyopharm-therapeutics-inc-kpti.html.

KPTI has been the topic of several recent analyst reports. Zacks Investment Research upgraded Karyopharm Therapeutics from a “hold” rating to a “buy” rating and set a $11.00 price target on the stock in a report on Thursday, July 6th. ValuEngine downgraded Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a report on Thursday, August 31st. Robert W. Baird reiterated an “outperform” rating and issued a $15.00 price target on shares of Karyopharm Therapeutics in a report on Tuesday, July 4th. Jefferies Group LLC reiterated a “buy” rating and issued a $16.00 price target on shares of Karyopharm Therapeutics in a report on Friday, July 14th. Finally, BidaskClub upgraded Karyopharm Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, August 25th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $15.67.

Karyopharm Therapeutics Inc. (NASDAQ KPTI) opened at 11.00 on Friday. The firm’s 50-day moving average price is $9.28 and its 200 day moving average price is $9.87. Karyopharm Therapeutics Inc. has a 12-month low of $6.27 and a 12-month high of $14.63. The stock’s market capitalization is $518.52 million.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its earnings results on Tuesday, August 8th. The company reported ($0.64) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.64). Karyopharm Therapeutics had a negative return on equity of 70.42% and a negative net margin of 67,267.47%. The company’s quarterly revenue was down 95.0% compared to the same quarter last year. During the same period last year, the business earned ($0.84) EPS. On average, equities analysts anticipate that Karyopharm Therapeutics Inc. will post ($2.68) EPS for the current year.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Institutional Ownership by Quarter for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Stock Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related stocks with our FREE daily email newsletter.